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Chronic Hypercapnic Respiratory 
Diseases
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Abstract
In the past, treatment of acute exacerbations of obstructive disease refractory 
to medical treatment was invasive mechanical ventilation. As a result of technical 
improvements, extracorporeal techniques for carbon dioxide removal have aroused as 
an attractive option to avoid worsening respiratory failure and respiratory acidosis and 
potentially prevent, shorten the duration of invasive mechanical ventilation (IMV), 
and serve as rescue therapy in patients with exacerbation of COPD and asthma. In this 
review, we will present a comprehensive summary of the pathophysiological rationale 
and evidence of ECCO2R in patients with severe exacerbations of these pathologies.
Keywords: COPD, asthma, ECCO2R, invasive mechanical ventilation,  
noninvasive mechanical ventilation
1. Introduction
Patients with obstructive lung diseases, such as asthma and chronic obstructive 
pulmonary disease (COPD), may experience acute exacerbations with severe hyper-
capnic respiratory failure. Hypercapnia results from acute worsening of expiratory 
flow limitation caused by the increased small airway resistance with consequent 
development of dynamic alveolar hyperinflation and intrinsic PEEP. In the most 
severe cases, these may be refractory to conventional therapies and mechanical 
ventilation, becoming life-threatening.
Extracorporeal carbon dioxide removal (ECCO2R) represents an attractive 
approach in this setting.
The last decade has seen an increasing interest in the provision of extracorporeal 
support for respiratory failure, as demonstrated by the progressively increasing num-
ber of scientific publications on this topic. In particular, remarkable interest has been 
focused on ECCO2R, due to the relative ease and efficiency in blood CO2 clearance 
granted by extracorporeal gas exchangers as compared to oxygen delivery (Table 1).
In recent years, new-generation ECCO2R devices have been developed. More effi-
cient veno-venous (VV-ECCO2R) devices have become available and have replaced 
the arteriovenous approach, having the advantage of not requiring arterial puncture.
They offer lower resistance to blood flow, have small priming volumes, and have a 
much more efficient gas exchange [1] with relatively low extracorporeal blood flows 
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(0.4–1 L/min). With ECCO2R the patient’s PaCO2 is principally determined by the rate 
of fresh gas flow through the membrane lung [2]. These devices are now comparable 
to renal dialysis equipment, which is routinely used safely as standard care in ICU.
This approach has been the subject of many animal experiments and human case 
series demonstrating improved arterial CO2 and work of breathing [3–6].
2. Pathophysiological rationale for ECCO2R
Both in asthma and COPD exacerbations, diffuse narrowing of the airways 
results in profound physiologic consequences. Airway narrowing prevents the lungs 
from completely emptying (“air trapping”) due to resistance to expiratory flow 
and bronchial closure at higher than average lung volumes. Air trapping results in 
dynamic hyperinflation (DHI) [7] which is the excessive increase in end-expiratory 
lung volume above the relaxation volume of the respiratory system, generating 
intrinsic positive end-expiratory pressure (auto-PEEP) [8]. As a result, the patient 
breathes at higher total lung volumes, depending on increased residual volume 
[9] which reduces tidal ventilation. The net effect is that the work of breathing 
increases significantly. The diaphragm, intercostal muscles, and even the abdominal 
muscles are overloaded causing respiratory muscle fatigue and dyspnea.
Pharmacotherapy with bronchodilators and systemic corticosteroids are the 
cornerstones of medical therapy, designed to reduce this pathophysiological airflow 
obstruction and improve symptoms.
Patients suffering from a combination of persistent or worsening hypercapnia, 
respiratory muscle fatigue, and a decline in mental status require mechanical venti-
lation (MV) along with lung-protective ventilator strategies (e.g., low-tidal-volume 
ventilation, relatively short inspiratory time and longer expiratory times) [10, 11].
The goal of mechanical ventilation is to provide adequate gas exchange while 
waiting for airflow obstruction to respond to bronchodilator therapy. However, 
mechanical ventilation may aggravate alveolar hyperinflation by worsening DHI, 
which may lead to worsened hypercapnia, barotrauma, and alveolar rupture leading 
to pneumothorax and further hemodynamic deterioration [12].
Furthermore, during mechanical ventilation, these patients receive sedatives or 
neuromuscular blockade to facilitate ventilatory support [13]. Sedation and paraly-
sis preclude mobilization, promoting muscular deconditioning and potentially 
contributing to the long-term cognitive sequelae of critical illness [14].
ECMO ECCO2R
Cannulas Large cannulas Double lumen catheter
Blood flow High extracorporeal flow 
(2000–>5000 ml/min)
Low flow, respiratory dialysis 
(250–1000 ml/min)
Membrane 
oxygenator
Large membrane oxygenator Medium size oxygenator
Oxygenation Full blood oxygenation No blood oxygenation
CO2 removal Full blood decarboxylation Partial blood decarboxylation
Heparin 
requirements
High Higher than ECMO
Setting High technicity, ECMO center Regular ICU
Table 1. 
ECMO and ECCO2R differences.
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When conventional therapeutic options are not successful, novel therapies such 
as extracorporeal membrane oxygenation are entertained as a possible salvage 
therapeutic modality.
During exacerbation relieving the native lung from at least part of the CO2 
elimination with ECCO2R could potentially improve the acid–base balance, reduce 
patient’s work of breathing with a consequent reduction in respiratory rate and ven-
tilatory drive, and lower alveolar ventilation. The application of ECCO2R may allow 
lower tidal volumes and respiratory rate, resulting in the extension of the expiratory 
time, suiting better the high expiratory time constant of the respiratory system 
with expiratory flow limitation. By these physiological mechanisms, ECCO2R can 
counteract the vicious circle of dynamic hyperinflation and its detrimental respira-
tory and cardiovascular consequences. The derived beneficial effects on respiratory 
mechanics, ventilatory muscle efficiency, work of breathing, and cardiovascular 
function may improve gas exchanges and relieve dyspnea, thus potentially prevent-
ing NIV failure or facilitate weaning from IMV, and, also by rapidly decreasing and 
weaning off sedation, reduce the rates of delirium, reduce feeding problems, and 
allow social contacts with friends and family, as well as allow sufficient physio-
therapy to reduce myopathy and critical care illness [14].
3. ECCO2R technical aspects and principle
ECCO2R is designed to remove carbon dioxide (CO2) and, unlike extracorporeal 
membrane oxygen (ECMO), does not provide significant oxygenation.
The device consists of a drainage cannula placed in a large central vein or artery, 
a membrane lung, and a return cannula into the venous system (Figure 1). Blood is 
pumped through the membrane lung, and CO2 is removed by diffusion. A flowing 
gas known as “sweep gas” containing little or no CO2 runs along the other side of 
the membrane, ensuring a diffusion gradient from blood to another side, allowing 
CO2 removal.
In contrast to ECMO, where the need for oxygenation requires high blood 
flow rates, ECCO2R allows much lower blood flow rates, a result of significant 
differences in CO2 and oxygen (O2) kinetics. Almost all the O2 in blood is carried 
by hemoglobin, which displays sigmoidal saturation kinetics. Assuming normal 
hemoglobin and venous O2, each liter of venous blood can only carry an extra 
40–60 ml of O2 before the hemoglobin is fully saturated. Blood flows of 5–7 L/min 
are therefore required to supply enough O2 for an average adult. Conversely, most 
CO2 is transported as dissolved bicarbonate, displaying linear kinetics without 
saturation. Considering that 1 L of blood is transported around 500 mL of CO2, a 
perfectly efficient system flow of 0.5 L/min would be enough to remove all of the 
CO2 produced [1, 15, 16]. Also, CO2 diffuses more readily than O2 across extracor-
poreal membranes because of higher solubility. However, in practice, ECCO2R is 
usually able to remove up to 25% of carbon dioxide production given the limitations 
of blood flow, blood CO2 content, hemoglobin, and membrane efficiency [17].
3.1 VV-ECCO2R
In the veno-venous configuration, blood is drawn from a central vein by a drain-
ing cannula, using a centrifugal or roller pump to generate flow across the mem-
brane. CO2 diffuses into the “sweep gas” and is returned into the venous circulation 
(Figure 1A). Single site cannulation is possible using a double lumen cannula. This 
approach allows low flow through the use of smaller cannulas (15–19F), commonly 
introduced via the right internal jugular vein. The setup is very similar to renal 
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replacement therapy, and in fact, some systems are trying to combine the two in 
one [18, 19] (NCT02590575). One of the advantages of VV-ECCO2R compared to 
the AV approach is the less invasiveness by the omission of the arterial cannulation 
and facilitates early mobilization of patients. It is also possible to set up an ECCO2R 
system through cannulation of two central veins, one for drainage and the other for 
reinfusion (femoral-femoral configuration).
3.2 AV-ECCO2R
One ECCO2R configuration is through percutaneous cannulation of the femo-
ral artery to the contralateral femoral vein and creating an arteriovenous (AV) 
bypass, equipped with an artificial gas exchanger membrane across the AV shunt 
which acts as a “sweep gas” to remove CO2 that has diffused out of the patient’s blood 
(Figure 1B). In this configuration, pumpless systems require an arteriovenous pres-
sure gradient ≥60 mmHg and a cardiac index >3 L/min/m2, which is unsuitable for 
hemodynamically unstable patients [16, 20]. Further, cannulation of a major artery 
can result in distal ischemia [21], although measuring the artery diameter with 
ultrasound and selecting a cannula that occupies no more than 70% of the lumen 
reduce this risk [22].
4. Indications and evidence
4.1 Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a significant worldwide 
health burden. Currently, it is the fourth leading cause of death worldwide, is the 
only leading cause of death that is rising, and will likely become the third cause of 
Figure 1. 
ECCO2R common configurations. (A) Minimally invasive veno-venous ECCO2R system with a single venous 
vascular access through a double lumen cannula that can be inserted in the internal jugular or femoral vein 
(B) Pumpless arteriovenous ECCO2R system with the placement of the membrane in the circuit connecting the 
femoral artery with the contralateral vein.
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death by 2020 [23, 24]. COPD is characterized by progressive destruction in the 
elastic tissue within the lung, causing respiratory failure.
Acute exacerbations of COPD (aeCOPD) constitute a significant cause of 
morbidity and mortality among these patients. Patients with moderate to severe 
acute exacerbations develop alveolar hyperinflation that may lead to increased work 
of breathing, muscle fatigue, and hypercapnia, creating a vicious loop refractory 
to medical treatment [25–27]. The standard respiratory support in this setting in 
order to break this cycle is noninvasive ventilation (NIV). However, despite the 
significantly decreased mortality with the emergence of NIV, up to 30% of patients 
with aeCOPD will “fail” and require intubation and invasive mechanical ventilation 
(IMV) [28–30]. For patients requiring respiratory support with IMV, in-hospital 
mortality in recent meta-analysis and observational studies has been reported to be 
as high as 25–39% [31–34].
Patients with COPD requiring IMV develop a considerable reduction in respi-
ratory muscle strength, having a higher risk of prolonged weaning and failure to 
wean compared to other causes of acute hypercapnic respiratory failure. Up to 
60% of the ventilatory time is devoted to these patients to the process of weaning 
[35], and they are very likely to require a tracheotomy. Having a prolonged time 
spent under IMV is not surprising an increase in the incidence of ventilator-
associated pneumonia and complications associated with the use of invasive 
mechanical ventilation such ventilator-induced lung injury (VILI), ventilator-
associated pneumonia (VAP), ventilator-associated diaphragmatic dysfunction 
(VIDD), and a range of neurological disorders associated with prolonged sedation 
and immobilization.
4.1.1 Evidence and clinical trials of ECCO2R in aeCOPD to date
One of the first reports on the application of ECCO2R to support respiratory 
function of a COPD patient was published in 1990 by Pesenti et al. [36]. However, 
the technique was abandoned due to technical complications.
As the medical community regained interest in ECCO2R, investigators began 
applying the technique to prevent intubation or to assist weaning from the ven-
tilator in patients with hypercapnic aeCOPD. Several studies in both VV and AV 
configurations were published, including a meta-analysis (Table 2).
4.1.2 ECCO2R to avoid IMV
Brederlau et al. [37] described their experience in three patients that failed 
NIV for severe aeCOPD. They applied a pumpless AV ECCO2R device with the 
goal of avoiding endotracheal intubation. Shortly after beginning ECCO2R, PaCO2 
fell significantly (from 91, 109, and 142 mmHg to 52, 59, and 83 mmHg, respec-
tively), while pH rose (from 7.2, 7.19, and 7.06 to 7.41, 7.43, and 7.34, respectively). 
Simultaneously, the respiratory rate dropped from 38, 45, and 37 breaths/min to 
15, 25, and 18 breaths/min, respectively. The ECCO2R flow ranged between 1.1 and 
1.6 L/min, with the sweep gas flow varying from 3 to 10 L/min.
Kluge et al. [5] in the same year evaluated the safety and efficacy of using AV 
pumpless extracorporeal lung assist (PECLA) in 21 COPD patients who did not 
respond to NIV compared to 21 matched controls. The use of PECLA was associated 
with a decrease in PaCO2 levels and improved pH after 24 h and obviated the need 
for intubation and IMV in 90% of the experimental arm. Although the experimen-
tal group demonstrated a shorter length of stay, a retrospective analysis with the 
control group showed no significant difference in mortality at 28 days (19% with 
ECCO2R vs. 24% without ECCO2R) or 6 months (both groups 33%).
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Study No of 
patients
ECCO2R characteristics Time on 
ECCO2R
Major results
Configuration Blood flow 
(mL/min)
Sweep flow 
(L/min)
Membrane (material); 
surface in m2
ECCO2R to avoid mechanical ventilation
Kluge et al. 
[5]
21 Femoral AV with 13- to 15-Fr 
arterial cannula and 13- to 
17-Fr venous cannula
1100 Not reported PMP*; 1.3 (iLA®) 9 days 19 (90%) PECLA patients did not require 
intubation
Two major and seven minor bleeding 
complications during PECLA
No significant difference in 28-day (24 
vs. 19%, p = 0.85), 6-month mortality (33 
vs. 33%), or hospital length of stay (23 vs. 
42 days, p = 0.06)
Significantly fewer tracheostomies in PECLA 
group (10 vs. 67%, p = 0.004)
Del Sorbo 
et al. [4]
25 Modified continuous VV 
hemofiltration system with 
membrane
lung via 14-Fr single dual-
lumen cannula (femoral)
255 8 PLP**; 1.35 (Hemodec 
DecapSmart®)
1–2 days Significantly higher risk of intubation in NIV-
only group (HR 0.27; 95% CI 0.07–0.98)
13 patients experienced adverse events: 3 had 
bleeding, 1 had vein perforation, and 9 had 
device malfunction
Braune 
et al. [39]
25 VV configuration via a 22 
or 24-Fr single dual-lumen 
cannula (femoral or jugular)
1300 Not reported PMP; 1.3 (Novalung 
iLA Activve)
8.5 days Intubation was avoided in 14 out of all 25 
ECCO2R patients (56%)
Seven ECCO2R patients were intubated 
because of progressive hypoxemia and four 
due to ventilatory failure despite ECCO2R and 
NIV
Nine ECCO2R patients (36%) suffered from 
major bleeding complications
90-day mortality rates were 28 vs. 28%
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Study No of 
patients
ECCO2R characteristics Time on 
ECCO2R
Major results
Configuration Blood flow 
(mL/min)
Sweep flow 
(L/min)
Membrane (material); 
surface in m2
ECCO2R to wean from mechanical ventilation
Abrams 
et al. [3]
5 VV configuration via a 20- 
to 24-Fr single dual-lumen 
jugular
catheter using lower flow on 
ECMO system
1700 1–7 PMP; 0.98 (Maquet 
PALP CardioHelp)
8 days Mean (SD) time to ambulation after ECCO2R 
initiation was 29.4 ± 12.6 h
Four patients were discharged home, and one 
underwent planned lung transplantation
Only two minor bleeding complications
Cardenas 
et al. [42]
1 VV configuration with 
pediatric dual-lumen jugular 
cannula
800 10 PMP; 1.8 (Quadrox-d, 
Maquet)
3.6 days Patient extubated 48 h after decannulation. 
No complications reported
Roncon 
et al. [43]
ECCO2R with mixed indications
Burki [38] 20 VV configuration via a 
15.5-Fr single dual-lumen 
catheter (femoral or jugular)
430 Not reported PLP with a base of 
siloxane layer; 0.59 
(ALung Hemolung 
RAS)
2–192 h 20 hypercapnic COPD patients received 
ECCO2R in three distinct groups: group 1 
(n = 7) NIV patients with
high risk of IMV; group 2 (n = 2) could not be 
weaned from NIV; and group 3 (n = 11) on 
IMV and failed to wean
IMV avoided in all patient in group 1
Both patients in group 2 weaned from NIV
In group 3, three patients weaned, and IMV 
was reduced in two patients
One patient died due to a retroperitoneal 
hemorrhage (during cannulation)
*PMP: poly-4-methyl-1-pentene.
**PLP: polypropylene.
Table 2. 
Relevant clinical studies of ECCO2R in COPD.
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In the study by Burki et al. [38], 20 hypercapnic patients with COPD were 
treated with ECCO2R using a 15.5-Fr dual-lumen cannula allowing a mean blood 
flow of 430 mL/min. Of the 20 patients recruited into the trial, 7 were at risk of MV 
despite NIV, 2 were difficult to wean from NIV, and 11 had failed liberation from 
MV. None of the patients failing NIV required endotracheal intubation, and both 
patients with difficult weaning from NIV were weaned. However, only 3 of the 11 
IMV patients were liberated successfully. Moreover, significant complications arose 
in a number of patients: bleeding requiring blood transfusion was reported in three 
patients, deep vein thrombosis was diagnosed in one patient after removal of the 
ECCO2R catheter, one patient experienced pneumothorax due to catheter insertion, 
and one died from hemorrhage when the iliac vein was perforated during ECCO2R 
catheter placement.
Del Sorbo et al. [4] examined 25 patients with NIV + ECCO2R versus NIV alone 
(historical controls n = 21) for prevention of intubation in aeCOPD. They reported 
that ECCO2R with a 14-Fr dual-lumen catheter and blood flow rates of 177–333 mL/
min not only improved respiratory acidosis but also reduced the need for intubation 
by 75% (12 vs. 33%; p = 0.047) and significantly reduced the in-hospital mortal-
ity (8 vs. 35%; p = 0.035). However, this came with a cost of 52% prevalence of 
ECCO2R-related side effects and led the authors to suggest the end point of future 
studies should be long-term mortality.
In the ECLAIR study, Braune et al. [39] showed that IMV was avoided in 56% 
of cases treated with ECCO2R but was associated with a higher incidence of com-
plications. However, several significant differences must be taken into account. 
In the latter study, there was an inclusion of patients with relative contraindi-
cations to NIV, and there was an unexpectedly high incidence of hypoxemic 
patients [40].
Finally, Morelli et al. [41] and colleagues confirmed the efficacy of ECCO2R 
(with a flow rate of 250–450 mL/min through a 13-Fr dual-lumen cannula) in 
reducing the PaCO2 in a series of 30 patients with acute hypercapnic respiratory 
failure due to aeCOPD, who refused endotracheal intubation after failing NIV. The 
duration of ECCO2R was 2–16 days, and it was possible to prevent endotracheal 
intubation in 27 patients.
4.1.3 ECCO2R to facilitate weaning from IMV
Cardenas et al. [42] made the first attempt to use modern ECLS components for 
VV ECCO2R in a patient with aeCOPD. They demonstrated a successful reduction 
in PaCO2, minute ventilation, and ventilator pressures.
Burki et al. [38] showed that in a subgroup of 11 patients receiving IMV, ECCO2R 
allowed the weaning from mechanical ventilator in only 3 patients.
Abrams and colleagues [3] reported five older patients (age 73 ± 8.7 years) 
with aeCOPD who failed NIV, requiring IMV. After an average of 16.5 ± 5.9 h 
of IMV, ECCO2R was initiated. By using a dual-lumen cannula (20–23 Fr) with 
blood flow rates of 1–1.7 L/min and with a sweep gas flow from 1 to 7 L/min, 
they were able to extubate all five patients within 24 h of treatment (median 
duration of MV post ECCO2R = 4 h, range 1.5–21.5 h). Once extubated, 
patients were rehabilitated while on ECCO2R, with a mean time to ambula-
tion of 29.4 ± 12.6 h after ECCO2R. Moreover, all patients survived to hospital 
discharge.
Using a pediatric VV ECMO system (with blood flow rates of 0.9 L/min through 
a 19 Fr dual-lumen cannula placed in the right jugular vein) in two patients with 
aeCOPD, Roncon-Albuquerque Jr. et al. reported early extubation after 72 h and 
patient mobilization out of bed at day 6 [43].
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4.1.4 Reviews of ECCO2R in COPD
Sklar et al. [44] reviewed 10 studies of ECCO2R for aeCOPD and a total of 87 
patients, to examine cumulative safety and efficacy. They reported that ECCO2R 
was able to prevent intubation in 65 (93%) of 70 patients and assist in successful 
extubation of 9 (53%) of 17 patients. There were a total of 11 major complications 
and 30 minor complications. Half of all patients experienced complications related 
to ECCO2R, and half of those complications were related to bleeding (21/41). No 
study showed any evidence of increased mortality or increased length of intensive 
care unit (ICU) or hospital stay with ECCO2R.
In a recent publication, Taccone et al. [45] performed a systematic review of 
ECCO2R in adult critically ill patients. Three of the six studies included in the 
review evaluated patients with COPD that developed hypercapnic respiratory fail-
ure [4, 5, 39]. In all the three studies, the reduction of PaCO2 was reported within a 
few hours following the initiation of ECCO2R. Median values decreased from 73 to 
88 mmHg to 34–66 mmHg. Regarding the duration of mechanical ventilation, only 
one described no significant difference between ECCO2R and the controlled group 
[4]. The need for endotracheal intubation was significantly reduced from 53/67 
(79%) to 16/71 (22% p < 0.001). However, neither ICU nor hospital length of stay 
was statistically significantly reduced.
Based on the existing data, we believe that the ideal trial for ECCO2R should be a 
randomized controlled trial designed such ECCO2R should be implemented within 12 h 
of intubation after failing to show improvement (i.e., pH < 7.25 for persistent acidosis) 
with conventional therapy. Given the risks associated with the technique, it should be 
instituted once patients fail conventional treatment and require IMV. Patients should 
be randomized to ECCO2R plus IMV or standard IMV. Given the high rate of mortal-
ity associated with invasive mechanical ventilation, the study should be powered to 
demonstrate a mortality benefit, and secondary endpoints include ventilator-free days, 
transfusion requirements, and rates of ventilator-associated events.
More data will be forthcoming on the application of ECCO2R in the management 
of patients with COPD exacerbations from a number of ongoing or planned clinical 
trials (Table 3).
4.2 Severe acute asthma
Asthma is an inflammatory disorder of the airways characterized by airway 
hyperactivity with bronchospasm, mucosal swelling, and mucus production.
The standard treatment of severe acute asthma consists of measures to reverse 
airflow obstruction. β2 agonists and steroids are the mainstays of treatment causing 
bronchodilation and anti-inflammatory effects, respectively [10]. Other available 
adjunct therapies including anticholinergics, magnesium sulfate, methylxanthines, 
ketamine, and heliox have been utilized with varying results [46].
Despite advances in asthma therapy, asthma mortality has remained stable in 
recent years. One reason is status asthmaticus, which can be unresponsive to initial 
treatment and may lead to hypercapnic respiratory failure despite maximal therapy.
Status asthmaticus, also known as severe acute asthma or near-fatal asthma, is 
a condition of progressively worsening bronchospasm and respiratory dysfunction 
due to asthma, which is unresponsive to standard conventional therapy and may 
progress to respiratory failure and the need for mechanical ventilation. The current 
indication of mechanical ventilation in a patient presenting with status asthmaticus 
is a clinical one and does not require a blood gas assessment. These include certain 
specific situations including alteration of consciousness, respiratory fatigue, or 
impending cardiopulmonary arrest.
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ClinicalTrials.
gov number
Title Type of study Hypothesis/primary 
outcome
Estimated 
enrollment
Device
ECCO2R to avoid mechanical ventilation
NCT02086084 Extracorporeal 
CO2 removal 
as an adjunct 
to noninvasive 
ventilation in 
acute severe 
exacerbations 
of COPD
Randomized, 
controlled trial
Addition of ECCO2R to NIV 
will shorten the duration of 
NIV and reduce the likelihood 
of intubation
Primary outcome: time to 
cessation of NIV defined as 
from NIV commencement to 
6 h without NIV
24 patients Hemolung 
RAS
NCT03584295 Early 
extubation 
by ECCO2R 
compared 
to IMV in 
patients with 
severe acute 
exacerbation 
of COPD 
(X-COPD)
Interventional, 
randomized 
with parallel 
assignment
Advantage of VV-ECCO2R 
in severe acute exacerbation 
of COPD requiring invasive 
mechanical ventilation (IMV) 
to facilitate early extubation in 
terms of reducing mortality or 
severe disability
Primary outcome: death or 
severe disability
202 patients Not specified
NCT02564406 Extracorporeal 
CO2 removal 
in hypercapnic 
patients
Interventional 
single-group 
trial
Retrospectively assess 
the efficacy and safety of 
noninvasive ventilation-
plus-extracorporeal CO2 
removal in patients who fail 
NIV and refuse endotracheal 
intubation
Primary outcome: number 
of patients who avoided 
endotracheal intubation
35 patients ProLUNG 
[Estor]
NCT03692117 Extracorporeal 
carbon dioxide 
removal in 
severe chronic 
obstructive 
pulmonary 
disease 
exacerbation
Prospective 
cohort study
Primary outcome: incidence 
of avoiding endotracheal 
intubation
30 patients Not specified
ECCO2R to facilitate liberation from mechanical ventilation
NCT02259335 Weaning from 
mechanical 
ventilation 
using 
extracorporeal 
CO2 removal 
(WeanPRO)
Interventional 
single-group 
trial
Weaning success avoiding 
reintubation after removal of 
ECCO2R
12 patients ProLUNG 
[Estor]
NCT02107222 The PALP™-
COPD trial 
(low flow 
CO2-removal 
(ECCO2-R) in 
exacerbated 
COPD) 
(PALP-COPD)
Multicenter, 
randomized, 
controlled trial
To evaluate the clinical effect 
of PALP in reducing the time 
on invasive ventilation in 
patients with an exacerbation 
of COPD requiring invasive 
mechanical ventilation
120 patients PALP
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Approximately, 4% of all patients hospitalized for acute asthma require mechan-
ical ventilation, which is associated with increased in-hospital mortality compared 
with patients who do not require mechanical ventilation (7 vs. 0.2%) [47].
Furthermore, mechanical ventilation may aggravate alveolar hyperinflation as 
it was described above. To prevent the potential side effects caused by mechanical 
ventilation, ECCO2R has been applied as rescue therapy.
Extracorporeal carbon dioxide removal as an adjunct to the ventilator for 
refractory asthma was first reported in 1981 [48]. Subsequently, there have been 
several case reports (Table 4). In the international Extracorporeal Life Support 
Organization (ELSO) registry, ECMO was used for asthma in 24 out of 1257 adult 
patients between 1986 and 2006. Before ECMO was started, the average pH was 
ClinicalTrials.
gov number
Title Type of study Hypothesis/primary 
outcome
Estimated 
enrollment
Device
ECCO2R as an alternative or adjunct to invasive mechanical ventilation
NCT03255057 Extracorporeal 
CO2 removal 
for mechanical 
ventilation 
avoidance 
during acute 
exacerbation 
of COPD 
(VENT-AVOID)
Multicenter 
randomized 
controlled trial
ECCO2R can be safely used 
to avoid or reduce time 
on invasive mechanical 
ventilation compared to 
COPD patients treated with 
standard-of-care mechanical 
ventilation alone
Primary outcome: ventilator-
free days at day 60 from 
randomization
500 
patients
Hemolung
ECCO2R physiological studies
NCT02586948 Physiological 
study of 
minimally 
invasive 
ECCO2R in 
exacerbations 
of COPD 
requiring 
invasive 
mechanical 
ventilation 
(EPHEBE)
Interventional 
single-group 
trial
The addition of minimally 
invasive ECCO2R is likely to 
limit dynamic hyperinflation 
in COPD patients requiring 
invasive mechanical 
ventilation for an acute 
exacerbation while improving 
gas exchange
Primary outcome: PEEPi at 
baseline and after ECCO2R by 
the device and adjustment of 
ventilator settings, expressed 
in cmH20
12 patients Hemolung
NCT02590575 “Low Flow” 
CO2 removal on 
RRT
Interventional 
single-group 
trial
Test the effectiveness of a 
membrane gas exchange 
device in the veno-venous 
circulation of continuous 
renal replacement therapy 
for the purpose of CO2 
elimination and pH 
compensation
The primary outcome is the 
modification of the PaCO2 
and/or the ventilator settings 
(tidal volume VT and plateau 
pressure Pplat)
20 patients Prismalung
Table 3. 
Ongoing clinical studies of ECCO2R in COPD.
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7.17 ± 0.16, PaCO2 119.7 ± 58 mmHg, and PaO2/FiO2 244 ± 180 despite mechani-
cal ventilation. Complications were described in 19 of 24 patients (79.2%) with a 
remarkable number of hemodynamic, hemorrhagic, and mechanical complications 
[49]. These data show that in patients treated with ECMO for status asthmaticus, 
hypercapnia, rather than hypoxemia, was the central exchange derangement, sug-
gesting that a less invasive technique like ECCO2R will be suitable, with fewer com-
plications. Although most of the clinical applications of ECCO2R for the treatment 
of obstructive lung diseases have been reported in patients with COPD, several 
cases describe ECCO2R in patients with near-fatal asthma [50–54] (Table 4).
The first cases reported were by using a pumpless extracorporeal life assist 
(pECLA) device. Although no complications were described in these case series, a 
possible major complication may arise as a consequence of the arterial cannulation, 
such as lower limb ischemia [53]. Brenner et al. reported two cases using a venous 
double lumen catheter with successful survival results.
Study ECCO2R technique Major findings
Sakai et al. 
[53]
Extracorporeal lung assist 
(ECLA); 22-Fr drainage 
and 18-Fr return femoro-
femoral cannula with a 
median blood flow rate of 
1.7–2 L/min
23-year old
Gas exchange with IMV before ECCO2R: pH 7.02, paCO2 100 mmHg, 
PaO2 50 mmHg (FiO2 100%)
Weaning achieved after 20 h of ECLA was commenced
Extubation 2 days after ECLA
No complications reported
Elliot et al. 
[52]
Femoral AV pumpless 
extracorporeal lung assist 
(PECLA)
15-Fr arterial cannula and 
17-Fr venous cannula with a 
mean extracorporeal blood 
flow of 1.5 L/min
Case 1: 74-year old. Gas exchange with IMV before ECCO2R: pH 6.87, 
paCO2 147 mmHg. Extubation after 48 h of ECLA. Complications: 
Coagulation of membrane that needed changing. Bleeding through 
femoral artery
Case 2: 52-year old. Gas exchange with IMV before ECCO2R: pH 7.2, 
paCO2 130 mmHg. ECCO2R duration: 5 days
Extubated on intensive care day 11. No complications reported
Jung et al. 
[54]
Femoral AV pumpless 
extracorporeal lung assist 
(PECLA)
15-Fr arterial cannula and 
17-Fr venous cannula with a 
mean extracorporeal blood 
flow of >1.5 L/min
42-year old
No gas exchange before IMV reported. Patient successfully extubated 
and transferred from the ICU on day 14 of admission
No complications reported
Brenner 
et al. [50]
Dual-lumen catheter 20–23 
Fr bicaval, inserted into 
the right internal jugular 
vein with blood flow of 
1.3–1.8 L/min
Case 1: 48-year old. Gas exchange with IMV before ECCO2R: pH 6.94, 
paCO2 147 mmHg, PaO2 416 mmHg (FiO2 100%). Successfully 
extubated while on ECCO2R and discharged from ICU. No 
complications reported
Case 2: 59-year old. Gas exchange with IMV before ECCO2R: pH 7.12, 
paCO2 78 mmHg, PaO2 112 mmHg (FiO2 100%). ECCO2R duration: 
9 days. Ventilator support discontinued on day 28 due to critical illness 
neuromyopathy
Schneider 
et al. [51]
Awake dual-lumen catheter 
22 Fr bicaval, inserted into 
the right internal jugular 
vein with blood flow of 
0.6–1.5 L/min
67-year old
Gas exchange before ECCO2R (on NIV): pH 7.24, paCO2 61 mmHg, 
PaO2 289 mmHg (FiO2 100%)
Thirty-four hours after initiating ECCO2R, the patient was weaned 
entirely from NIV, and the cannula could be removed without any 
complication. On day 4, the patient was discharged from the ICU 
without the need for supplemental oxygen and 6 days later, discharged 
from hospital without any impairment
IMV, invasive mechanical ventilation; NIV, noninvasive mechanical ventilation.
Table 4. 
Case series of ECCO2R for near-fatal asthma.
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Taking into account the deleterious effects of mechanical ventilation and seda-
tion, and the advantages of keeping the patient awake, recently, an awake approach 
using a double lumen cannula has been described [51]. NIV was used as ventilatory 
support. Thirty-four hours after starting the ECCO2R system, the patient was 
weaned entirely from NIV, and the cannula was removed without complications. 
The patient was discharged from the ICU on day 4 without supplemental oxygen 
and left the hospital on day 10. Although this is a tempting approach, several issues 
should be taken into account. Unexpected cannula displacement may be provoked 
by an interactive patient, resulting in significant hemorrhage and lethal shock, as a 
time to react is short. Patient discomfort, pain, and anxiety in the “awake” approach 
might be in such extent that starting deep sedation and mechanical ventilation is 
inevitable, losing all the advantages described before.
5. Complications
Although ECCO2R seems to be effective in improving or mitigating hypercapnic 
acidosis and possibly in reducing the rate of endotracheal intubation, its use is 
associated with a range of vascular, hematological, and other complications.
Arterial cannulation is associated with higher risk than venous catheterization, 
with specific complications including distal limb ischemia, compartment syndrome 
of the lower limb requiring fasciotomy, or limb amputation as devastating conse-
quences [16].
The occurrence of bleeding events is the most frequent complications of 
ECCO2R. The low flow renders systemic anticoagulation mandatory, increasing the 
risk of significant bleeding including cerebral, gastrointestinal, and nasopharyngeal 
bleeds. In the studies of ECCO2R to date, the rate of clinically significant hemor-
rhagic complications ranges between 2 and 50% [44].
Thrombocytopenia and heparin-induced thrombocytopenia are also commonly 
observed.
Conversely, thrombus formation is higher at lower blood flow rates because of 
increased exposure time to the membrane lung and circuit. Clots may detach and 
enter the patient’s bloodstream, plugging the membrane or obstructing the cannula 
if anticoagulation is not achieved.
6. Conclusions
In the past, ECCO2R was a complex technique requiring intensive monitoring 
and surgical expertise. Due to a high rate of complications, it was avoided by all but 
a few high expertise centers. With newer simplified system, devices are placed like 
temporary dialysis catheters and can be inserted by most intensivists.
In summary, minimally invasive ECCO2R appears very promising for patients 
with acute exacerbation of obstructive diseases refractory to conventional treat-
ment, but systemic evaluation is needed to prove its efficacy and determine the 
actual risks.
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Nomenclature
AV-ECCO2R arteriovenous extracorporeal carbon dioxide removal
COPD chronic obstructive pulmonary disease
CO2 carbon dioxide
DHI dynamic hyperinflation
ECCO2R extracorporeal carbon dioxide removal
ECMO extracorporeal membrane oxygenation
IMV invasive mechanical ventilation
NIV noninvasive ventilation
PECLA pumpless extracorporeal lung assist
PEEP positive end-expiratory pressure
PLP polypropylene
PMP poly-4-methyl-1-pentene
VV-ECCO2R veno-venous extracorporeal carbon dioxide removal
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